File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: High-intensity focused ultrasound for hepatocellular carcinoma: A single-center experience
  • Basic View
  • Metadata View
  • XML View
TitleHigh-intensity focused ultrasound for hepatocellular carcinoma: A single-center experience
 
AuthorsNg, KKC1
Poon, RTP1
Chan, SC1
Chok, KSH1
Cheung, TT1
Tung, H1
Chu, F1
Tso, WK1
Yu, WC1
Lo, CM1
Fan, ST1
 
Issue Date2011
 
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.annalsofsurgery.com
 
CitationAnnals Of Surgery, 2011, v. 253 n. 5, p. 981-987 [How to Cite?]
DOI: http://dx.doi.org/10.1097/SLA.0b013e3182128a8b
 
AbstractObjective: This study aims to evaluate the outcome of patients with hepatocellular carcinoma (HCC) treated by high-intensity focused ultrasound (HIFU) in a single tertiary referral center. Background: HIFU is the latest developed local ablation technique for unresectable HCC. The initial experience on its efficacy is promising, but the survival benefit of patients undergoing HIFU for HCC is poorly defined. Methods: From October 2006 to December 2008, 49 patients received HIFU for unresectable HCC. Each patient underwent a single session of HIFU with a curative intent. Treatment efficacy and survival outcome were evaluated. Clinicopathologic factors affecting the primary technique effectiveness and overall survival rates were investigated by univariate analysis. Results: The median size of the treated tumors was 2.2 cm, ranging from 0.9 to 8 cm. The majority of patients had single tumors (n = 41, 83.6%). Thirty-one patients (63.2%) had artificial right pleural effusion during HIFU treatment to reduce damage to the lung and diaphragm. The hospital mortality rate was 2% (n = 1) and the complication rate was 8.1% (n = 4). The primary technique effectiveness rate was 79.5% (39 of 49 patients). It increased from 66.6% in the initial series to 89.2% in the last 28 patients. Tumor size (3.0 cm) was the significant risk factor affecting the complete ablation rate. The 1- and 3-year overall survival rates were 87.7% and 62.4%, respectively. Child-Pugh liver function grading was the significant prognostic factor influencing the overall survival rate. Conclusions: HIFU is an effective treatment modality for unresectable HCC with a high technique effectiveness rate and favorable survival outcome. © 2011 Lippincott Williams & Wilkins.
 
ISSN0003-4932
2013 Impact Factor: 7.188
 
DOIhttp://dx.doi.org/10.1097/SLA.0b013e3182128a8b
 
ISI Accession Number IDWOS:000289510600021
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorNg, KKC
 
dc.contributor.authorPoon, RTP
 
dc.contributor.authorChan, SC
 
dc.contributor.authorChok, KSH
 
dc.contributor.authorCheung, TT
 
dc.contributor.authorTung, H
 
dc.contributor.authorChu, F
 
dc.contributor.authorTso, WK
 
dc.contributor.authorYu, WC
 
dc.contributor.authorLo, CM
 
dc.contributor.authorFan, ST
 
dc.date.accessioned2011-07-27T01:36:46Z
 
dc.date.available2011-07-27T01:36:46Z
 
dc.date.issued2011
 
dc.description.abstractObjective: This study aims to evaluate the outcome of patients with hepatocellular carcinoma (HCC) treated by high-intensity focused ultrasound (HIFU) in a single tertiary referral center. Background: HIFU is the latest developed local ablation technique for unresectable HCC. The initial experience on its efficacy is promising, but the survival benefit of patients undergoing HIFU for HCC is poorly defined. Methods: From October 2006 to December 2008, 49 patients received HIFU for unresectable HCC. Each patient underwent a single session of HIFU with a curative intent. Treatment efficacy and survival outcome were evaluated. Clinicopathologic factors affecting the primary technique effectiveness and overall survival rates were investigated by univariate analysis. Results: The median size of the treated tumors was 2.2 cm, ranging from 0.9 to 8 cm. The majority of patients had single tumors (n = 41, 83.6%). Thirty-one patients (63.2%) had artificial right pleural effusion during HIFU treatment to reduce damage to the lung and diaphragm. The hospital mortality rate was 2% (n = 1) and the complication rate was 8.1% (n = 4). The primary technique effectiveness rate was 79.5% (39 of 49 patients). It increased from 66.6% in the initial series to 89.2% in the last 28 patients. Tumor size (3.0 cm) was the significant risk factor affecting the complete ablation rate. The 1- and 3-year overall survival rates were 87.7% and 62.4%, respectively. Child-Pugh liver function grading was the significant prognostic factor influencing the overall survival rate. Conclusions: HIFU is an effective treatment modality for unresectable HCC with a high technique effectiveness rate and favorable survival outcome. © 2011 Lippincott Williams & Wilkins.
 
dc.description.naturepostprint
 
dc.identifier.citationAnnals Of Surgery, 2011, v. 253 n. 5, p. 981-987 [How to Cite?]
DOI: http://dx.doi.org/10.1097/SLA.0b013e3182128a8b
 
dc.identifier.doihttp://dx.doi.org/10.1097/SLA.0b013e3182128a8b
 
dc.identifier.epage987
 
dc.identifier.hkuros187648
 
dc.identifier.isiWOS:000289510600021
 
dc.identifier.issn0003-4932
2013 Impact Factor: 7.188
 
dc.identifier.issue5
 
dc.identifier.openurl
 
dc.identifier.pmid21394012
 
dc.identifier.scopuseid_2-s2.0-79954631974
 
dc.identifier.spage981
 
dc.identifier.urihttp://hdl.handle.net/10722/135541
 
dc.identifier.volume253
 
dc.languageeng
 
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.annalsofsurgery.com
 
dc.publisher.placeUnited States
 
dc.relation.ispartofAnnals of Surgery
 
dc.relation.referencesReferences in Scopus
 
dc.rightsThis is a non-final version of an article published in final form in Annals of Surgery, 2011, v. 253 n. 5, p. 981-987
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.subject.meshCarcinoma, Hepatocellular - mortality - pathology - therapy
 
dc.subject.meshCohort Studies
 
dc.subject.meshHigh-Intensity Focused Ultrasound Ablation - methods
 
dc.subject.meshLiver Neoplasms - mortality - pathology - therapy
 
dc.subject.meshPalliative Care
 
dc.titleHigh-intensity focused ultrasound for hepatocellular carcinoma: A single-center experience
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Ng, KKC</contributor.author>
<contributor.author>Poon, RTP</contributor.author>
<contributor.author>Chan, SC</contributor.author>
<contributor.author>Chok, KSH</contributor.author>
<contributor.author>Cheung, TT</contributor.author>
<contributor.author>Tung, H</contributor.author>
<contributor.author>Chu, F</contributor.author>
<contributor.author>Tso, WK</contributor.author>
<contributor.author>Yu, WC</contributor.author>
<contributor.author>Lo, CM</contributor.author>
<contributor.author>Fan, ST</contributor.author>
<date.accessioned>2011-07-27T01:36:46Z</date.accessioned>
<date.available>2011-07-27T01:36:46Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Annals Of Surgery, 2011, v. 253 n. 5, p. 981-987</identifier.citation>
<identifier.issn>0003-4932</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/135541</identifier.uri>
<description.abstract>Objective: This study aims to evaluate the outcome of patients with hepatocellular carcinoma (HCC) treated by high-intensity focused ultrasound (HIFU) in a single tertiary referral center. Background: HIFU is the latest developed local ablation technique for unresectable HCC. The initial experience on its efficacy is promising, but the survival benefit of patients undergoing HIFU for HCC is poorly defined. Methods: From October 2006 to December 2008, 49 patients received HIFU for unresectable HCC. Each patient underwent a single session of HIFU with a curative intent. Treatment efficacy and survival outcome were evaluated. Clinicopathologic factors affecting the primary technique effectiveness and overall survival rates were investigated by univariate analysis. Results: The median size of the treated tumors was 2.2 cm, ranging from 0.9 to 8 cm. The majority of patients had single tumors (n = 41, 83.6%). Thirty-one patients (63.2%) had artificial right pleural effusion during HIFU treatment to reduce damage to the lung and diaphragm. The hospital mortality rate was 2% (n = 1) and the complication rate was 8.1% (n = 4). The primary technique effectiveness rate was 79.5% (39 of 49 patients). It increased from 66.6% in the initial series to 89.2% in the last 28 patients. Tumor size (3.0 cm) was the significant risk factor affecting the complete ablation rate. The 1- and 3-year overall survival rates were 87.7% and 62.4%, respectively. Child-Pugh liver function grading was the significant prognostic factor influencing the overall survival rate. Conclusions: HIFU is an effective treatment modality for unresectable HCC with a high technique effectiveness rate and favorable survival outcome. &#169; 2011 Lippincott Williams &amp; Wilkins.</description.abstract>
<language>eng</language>
<publisher>Lippincott Williams &amp; Wilkins. The Journal&apos;s web site is located at http://www.annalsofsurgery.com</publisher>
<relation.ispartof>Annals of Surgery</relation.ispartof>
<rights>This is a non-final version of an article published in final form in Annals of Surgery, 2011, v. 253 n. 5, p. 981-987</rights>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<subject.mesh>Carcinoma, Hepatocellular - mortality - pathology - therapy</subject.mesh>
<subject.mesh>Cohort Studies</subject.mesh>
<subject.mesh>High-Intensity Focused Ultrasound Ablation - methods</subject.mesh>
<subject.mesh>Liver Neoplasms - mortality - pathology - therapy</subject.mesh>
<subject.mesh>Palliative Care</subject.mesh>
<title>High-intensity focused ultrasound for hepatocellular carcinoma: A single-center experience</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0003-4932&amp;volume=253&amp;issue=5&amp;spage=981&amp;epage=987&amp;date=2011&amp;atitle=High-intensity+focused+ultrasound+for+hepatocellular+carcinoma:+a+single-center+experience</identifier.openurl>
<description.nature>postprint</description.nature>
<identifier.doi>10.1097/SLA.0b013e3182128a8b</identifier.doi>
<identifier.pmid>21394012</identifier.pmid>
<identifier.scopus>eid_2-s2.0-79954631974</identifier.scopus>
<identifier.hkuros>187648</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-79954631974&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>253</identifier.volume>
<identifier.issue>5</identifier.issue>
<identifier.spage>981</identifier.spage>
<identifier.epage>987</identifier.epage>
<identifier.isi>WOS:000289510600021</identifier.isi>
<publisher.place>United States</publisher.place>
<bitstream.url>http://hub.hku.hk/bitstream/10722/135541/1/Content.pdf</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong